- Home
- MEGL vs CLNN Comparison
MEGL vs CLNN Comparison
Compare MEGL & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MEGL | CLNN |
|---|---|---|
| Founded | 2016 | 2012 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.3M | 57.4M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MEGL | CLNN |
|---|---|---|
| Price | $0.16 | $3.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.20 |
| AVG Volume (30 Days) | ★ 703.6K | 82.0K |
| Earning Date | 11-10-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $200,000.00 |
| Revenue This Year | N/A | $24.70 |
| Revenue Next Year | N/A | $9,228.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.16 | $3.02 |
| 52 Week High | $1.54 | $13.50 |
Technical Indicators
Market Signals| Indicator | MEGL | CLNN |
|---|---|---|
| Relative Strength Index (RSI) | 13.11 | 50.72 |
| Support Level | N/A | $3.13 |
| Resistance Level | $1.35 | $4.05 |
| Average True Range (ATR) | 0.10 | 0.28 |
| MACD | -0.05 | 0.06 |
| Stochastic Oscillator | 0.69 | 82.61 |
Price Performance
Historical ComparisonAbout MEGL Magic Empire Global Limited
Magic Empire Global Ltd is a financial services provider in Hong Kong which principally engage in the provision of corporate finance advisory services and underwriting services. The company's offerings mainly comprise of IPO sponsorship services, Financial advisory and independent financial advisory services, Compliance advisory services, Underwriting services, Corporate service.
About CLNN Clene Inc.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.